Successful treatment of resistant pseudogout with anakinra

Arthritis and Rheumatism

Volumn 58, Issue 2, 2008, Pages 631-633

  McGonagle, Dennis ^a,b   Tan, Ai Lyn ^a   Madden, Julie ^a   Emery, Paul ^a   McDermott, Michael F ^c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b CALDERDALE ROYAL HOSPITAL   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CORTICOSTEROID; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTHROPATHY; ARTICLE; CASE REPORT; DRUG EFFICACY; HUMAN; INTERPHALANGEAL JOINT; MALE; PRIORITY JOURNAL; PSEUDOGOUT; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; CHONDROCALCINOSIS; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MIDDLE AGED;

EID: 39749175570     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23119     Document Type: Article

References (14)

1. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.
2. Boschan C, Witt O, Lohse P, Foeldvari I, Zappel H, Schweigerer L. Neonatal-onset multisystem inflammatory disease (NOMID) due to a novel S331R mutation of the CIAS 1 gene and response to interleukin-1 receptor antagonist treatment. Am J Med Genet A 2006;140:883-6.
3. Ramos E, Arostegui JI, Campuzano S, Rius J, Bousono C, Yague J. Positive clinical and biochemical responses to anakinra in a 3-yr-old patient with cryopyrin-associated periodic syndrome (CAPS) [letter]. Rheumatology (Oxford) 2005;44:1072-3.
4. Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol 1986;13:804-5.
5. Rosenthal AK. Update in calcium deposition diseases [review]. Curr Opin Rheumatol 2007;19:158-62.
6. Chollet-Janin A, Finckh A, Dudler J, Guerne PA. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum 2007;56:688-92.
7. Church LD, Churchman SM, Hawkins PN, McDermott MF. Hereditary auto-inflammatory disorders and biologies [review]. Springer Semin Immunopathol 2006;27:494-508.
8. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-25.
9. Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis? [review]. Best Pract Res Clin Rheumatol 2006;20:879-96.
10. McDermott MF. A common pathway in periodic fever syndromes [review]. Trends Immunol 2004;25:457-60.
11. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006;3:e297.
12. McGonagle D, Savic S, McDermott MF. The NLR network and the immunological disease continuum of adaptive and innate immune-mediated inflammation against self. Semin Immunopathol 2007;29:303-13.
13. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28.
14. McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007;66:1683-4.